Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia

International Clinical Psychopharmacology

Volumn 14, Issue 6, 1999, Pages 357-360

  Poyurovsky, M ^a,c   Weizman, A ^b,c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

5 HT3; Antagonist; Granisetron; Neuroleptic induced akathisia; Serotonergic system

Indexed keywords

BENZODIAZEPINE; BIPERIDEN; FLUPHENAZINE; GRANISETRON; HALOPERIDOL; NEUROLEPTIC AGENT; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TRIHEXYPHENIDYL;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MALE; PARANOID SCHIZOPHRENIA; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT;

ACUTE DISEASE; ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; FEMALE; GRANISETRON; HUMANS; MALE; PILOT PROJECTS; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 0032737602     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199911000-00006     Document Type: Article

References (26)

1. Alon E, Himmelseher S (1992) Ondansetron in the treatment of postoperative vomiting: A randomized, double-blind comparison with dropcridol and metocleopramide. Anesth Analg 75:561-565.
2. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
3. Briskin J, Curtis JL (1997) Augmentation of clozapine therapy with ondansetron. Am J Psychiatry 154:1171.
4. Bymaster FP, Calligaro DO, Falcone JF, March RD, Moore NA, Tye NC, et al. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96.
5. Dubovsky SL, Thomas M (1995) Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 56:38-48.
6. Farde L, Nordström AL., Weisel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
7. Halstead SM, Barnes TRE, Speller JC (1994) Akathisia: Prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry 164:177-183.
8. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
9. Kapur S (1996) 5-HT2 antagonism and EPS benefits: Is there a causal connection? Psychopharmacology (Berl) 124:35-39.
10. Leigh TJ, Link CG, Fell GL (1992) Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG. Br J Clin Pharmacol 34:65-70.
11. Marshall RJ (1983) The pharmacology of mianserin - An update. Br J Clin Pharmacol 15:263S-268S.
12. Meltzer H (1994) An overview of the mechanism of action of clozapine. J Clin Psychiatry 55 (Suppl B):47-53.
13. Miller GH, Fleischhacker WW, Ehrmann H, Kane JM (1990) Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 26:373-376.
14. Minabe Y, Ashby CR, Wang RY (1992) Effects produced by acute and chronic treatment with granisetron alone and in combination with haloperidol on midbrain dopamine neurons. Eur Neuropsychopharmacol 2:127-133.
15. Overall JE, Gorham DE (1962) The brief psychiatric rating scale. Psychol Reports 10:799-812.
16. Palacious IM, Waeber C, Hoyer D, Mengod O (1990) Distribution of serotonin receptors. Ann NY Acad Sci 600:36-52.
17. Perez EA (1998) A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Safety 18:43-56.
18. Poyurovsky M, Weizman A (1997) Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: Open-label study of buspirone and mianserin. Int Clin Psychopharmacol 12:236-238.
19. Poyurovsky M, Fucs C, Weizman A (1998) Low-dose mianserin in the treatment of acute neuroleptic-induced akathisia. J Clin Psychopharmacol 18:253-254.
20. Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A (1999) Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry 174:238-242.
21. Salzman SK, Kelly G, Chavin J, Wang L, Puniak MA, Agresta CA, Azim S (1994) Characterization of mianserin neuroprotection in experimental spinal trauma: Dose/route response and late treatment. J Pharmacol Exp Therapeut 269:322-328.
22. Silva SR, Futuro-Neto HA, Pires JG (1995) Effects of 5-HT3 receptor antagonists on neuroleptic-induced catalepsy in mice. Neuropharmacol 34:97-99.
23. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (Suppl):11-19.
24. Smith-Kline Beecham Pharmaceuticals (1992) Clinical Study Synopsis. Data on file. Protocol 288. Publisher: Location ?
25. Weiss D, Aizenberg D, Hermesh H, Zemishlany Z, Munitz H, Radwan M, Weizman A (1995) Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 166:352-357.
26. Zoldan J, Friedberg G, Livneh M, Mclamed E (1995) Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45:1305-1308.